Genomic regions associated with multiple sclerosis are active in b cells

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Disanto, Giulio ^a,b   Sandve, Geir Kjetil ^c   Berlanga Taylor, Antonio J ^a,d   Morahan, Julia M ^a,b   Dobson, Ruth ^e   Giovannoni, Gavin ^e   Ramagopalan, Sreeram V ^a,b,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; B LYMPHOCYTE; CELL TYPE; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENHANCER REGION; FIBROBLAST; GENE CONTROL; GENE FUNCTION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; KERATINOCYTE; LIVER CELL; MULTIPLE SCLEROSIS; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; BIOLOGICAL MODEL; CELL CULTURE; CELL LINE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; GENETIC TRANSCRIPTION; GENETICS; GENOMICS; IMMUNE SYSTEM; METABOLISM; MONTE CARLO METHOD; TUMOR CELL LINE;

B-LYMPHOCYTES; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; ENHANCER ELEMENTS, GENETIC; GENETIC VARIATION; GENETICS; GENOMICS; HUMANS; IMMUNE SYSTEM; MODELS, GENETIC; MONTE CARLO METHOD; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 84857744447     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032281     Document Type: Article

References (21)

1. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G, (2010) Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 9: 727-739.
2. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
3. Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F, (2008) B cells and multiple sclerosis. Lancet Neurol 7: 852-858.
4. von Budingen HC, Bar-Or A, Zamvil SS, (2011) B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol.
5. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688.
6. Barun B, Bar-Or A, (2011) Treatment of multiple sclerosis with Anti-CD20 antibodies. Clin Immunol.
7. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al. (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447: 799-816.
8. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, et al. (2011) Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473: 43-49.
9. Sandve GK, Gundersen S, Rydbeck H, Glad IK, Holden L, et al. (2010) The Genomic HyperBrowser: inferential genomics at the sequence level. Genome Biol 11: R121.
10. Kasper LH, Shoemaker J, (2010) Multiple sclerosis immunology: The healthy immune system vs the MS immune system. Neurology 74 (Suppl 1): S2-8.
11. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, et al. (2005) Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62: 865-870.
12. Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, et al. (2010) The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One 5: e11986.
13. Brettschneider J, Tumani H, Kiechle U, Muche R, Richards G, et al. (2009) IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One 4: e7638.
14. Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, et al. (2011) Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 17: 335-343.
15. Sellebjerg F, Bornsen L, Khademi M, Krakauer M, Olsson T, et al. (2009) Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73: 2003-2010.
16. Joseph FG, Hirst CL, Pickersgill TP, Ben-Shlomo Y, Robertson NP, et al. (2009) CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 80: 292-296.
17. Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, et al. (2011) Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134: 2755-2771.
18. De Jager PL, Baecher-Allan C, Maier LM, Arthur AT, Ottoboni L, et al. (2009) The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A 106: 5264-5269.
19. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395-400.
20. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, et al. (2010) Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 67: 707-714.
21. Schneider R, Mohebiany AN, Ifergan I, Beauseigle D, Duquette P, et al. (2011) B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients. J Immunol 187: 4119-4128.